>"Sanofi and GlaxoSmithKline still expect phase 3 trial results for their COVID-19 vaccine in the first quarter of 2022. Researchers in England are looking to find combinations of existing antivirals that can fight the virus. Plus more."
>"Sanofi and GlaxoSmithKline still expect phase 3 trial results for their COVID-19 vaccine in the first quarter of 2022. Researchers in England are looking to find combinations of existing antivirals that can fight the virus. Plus more."
>"The US Food and Drug Administration on Thursday authorized Merck's antiviral pill, molnupiravir, to treat Covid-19 "for the treatment of mild-to-moderate _...Read More_
>"The US Food and Drug Administration on Thursday authorized Merck's antiviral pill, molnupiravir, to treat Covid-19 "for the treatment of mild-to-moderate _...Read More_